This is a preview of subscription content, log in via an institution to check access.
Accession codes
References
Gutiérrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010; 24: 629–637.
Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009; 114: e20–e26.
Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008; 105: 12885–12890.
O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT . c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839–843.
Benjamini Y, Hochberg Y . Controlling the false discovery rate: a powerful apporach to multiple testing. J Roy Statist Soc Ser B (Methodological) 1995; 57: 289–300.
Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010; 18: 367–381.
Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128–2136.
Loffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermuller J, Kretzschmar AK et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007; 110: 1330–1333.
Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001; 107: 789–800.
Acknowledgements
We thank JF van Galen and MM Wattel from the Erasmus Medical Center for performing additional FISH analysis.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Professor Dr P Sonneveld has served on advisory boards of Johnson & Johnson and Millennium Pharmaceuticals.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Corthals, S., Sun, S., Kuiper, R. et al. MicroRNA signatures characterize multiple myeloma patients. Leukemia 25, 1784–1789 (2011). https://doi.org/10.1038/leu.2011.147
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.147
- Springer Nature Limited
This article is cited by
-
Roles of miRNA dysregulation in the pathogenesis of multiple myeloma
Cancer Gene Therapy (2021)
-
Genome-wide identification of potential biomarkers in multiple myeloma using meta-analysis of mRNA and miRNA expression data
Scientific Reports (2021)
-
miRNA-202 in bone marrow stromal cells affects the growth and adhesion of multiple myeloma cells by regulating B cell-activating factor
Clinical and Experimental Medicine (2016)
-
Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells
Pathology & Oncology Research (2016)
-
MicroRNA theragnostics for the clinical management of multiple myeloma
Leukemia (2014)